Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars (LADISLAO)
Keloid
About this trial
This is an interventional treatment trial for Keloid focused on measuring Keloid, Scar
Eligibility Criteria
Inclusion Criteria:
- Keloids size equal or major than 1 cm
- Keloids less than 5 years old
- Keloids in trunk
Exclusion Criteria:
- Keloid with a surgical indication
- Hypertrophic scars
- Scars after burn wounds
- Pregnancy
- Lactation
- Use of systemic chemotherapeutics or chronic use of systemic corticosteroids or immunosuppressive medication
- Known hypersensitivity for triamcinolone or pirfenidone
- Severe comorbidity not controlled
- Inflammatory acne
- Diabetes Mellitus
- Hypertension
- Renal, hepatic or respiratory failure
- Topical treatment 4 weeks before recruitment
- Previous treatment with intralesional steroids
Sites / Locations
- Centro Dermatológico "Dr. Ladislao de la Pascua"Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Intralesional Triamcinolone
Topical Pirfenidone
Triamcinolone + Pirfenidone
A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.